NR2F1 regulatory antisense RNA 1 (NR2F1-AS1)

NR2F1 regulatory antisense RNA 1 (NR2F1-AS1) is a long non-coding RNA located adjacent to the NR2F1 gene, often transcribed in a divergent orientation but not overlapping in humans[2]. It is involved in the regulation of multiple cellular pathways, particularly in cancer, where it can act as an “oncogenic” lncRNA. NR2F1-AS1 promotes cancer cell proliferation, migration, invasion, and metastasis, and can modulate chemoresistance by sponging tumor-suppressive microRNAs (e.g., miR-485-5p, miR-218-5p, miR-363)[1][3][7]. In certain cancers like breast, lung, and hepatocellular carcinoma, upregulation of NR2F1-AS1 is correlated with increased malignancy and adverse prognosis[3][5][7]. Mechanistically, it can recruit proteins such as PTBP1 to enhance NR2F1 mRNA translation, thereby affecting key regulatory transcription factors and signaling axes like the AKT/mTOR and PI3K/AKT/GSK-3β pathways[5][7]. Beyond oncology, NR2F1-AS1 (lnc-NR2F1) has also been implicated in neurodevelopment, with genetic disruption contributing to neurodevelopmental disorders; overexpression enhances neuronal maturation and neurite outgrowth independently of the NR2F1 protein itself[2]. Currently, NR2F1-AS1 is not a direct therapeutic target (such as a receptor, enzyme, or transporter), but it functions as a regulatory RNA involved in diverse disease-relevant molecular pathways. **Note:** Drugs directly targeting NR2F1-AS1 are not reported in the literature as of the current date, nor are there established biomarkers or specific safety concerns related to NR2F1-AS1 as a therapeutic target[7].

Other names

NAS1FLJ42709NR2F1 antisense RNA 1lnc-NR2F1

MicroRNA sponging (e.g., miR-485-5p, miR-218-5p, miR-363, miR-423-5p), Regulation of mRNA translation (e.g., NR2F1 translation via PTBP1 recruitment), Modulation of oncogenic signaling pathways (e.g., AKT/mTOR, PI3K/AKT/GSK-3β)